369 related articles for article (PubMed ID: 15729367)
1. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
Oosterhoff D; Pinedo HM; Witlox MA; Carette JE; Gerritsen WR; van Beusechem VW
Gene Ther; 2005 Jun; 12(12):1011-8. PubMed ID: 15729367
[TBL] [Abstract][Full Text] [Related]
2. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
3. GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model.
Cascante A; Abate-Daga D; Garcia-Rodríguez L; González JR; Alemany R; Fillat C
Gene Ther; 2007 Oct; 14(20):1471-80. PubMed ID: 17713568
[TBL] [Abstract][Full Text] [Related]
4. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.
Wildner O; Morris JC
J Gene Med; 2000; 2(5):353-60. PubMed ID: 11045429
[TBL] [Abstract][Full Text] [Related]
5. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.
Geoerger B; van Beusechem VW; Opolon P; Morizet J; Laudani L; Lecluse Y; Barrois M; Idema S; Grill J; Gerritsen WR; Vassal G
J Gene Med; 2005 May; 7(5):584-94. PubMed ID: 15651070
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
8. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
Chen MJ; Green NK; Reynolds GM; Flavell JR; Mautner V; Kerr DJ; Young LS; Searle PF
Gene Ther; 2004 Jul; 11(14):1126-36. PubMed ID: 15164095
[TBL] [Abstract][Full Text] [Related]
9. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency.
van Beusechem VW; van den Doel PB; Grill J; Pinedo HM; Gerritsen WR
Cancer Res; 2002 Nov; 62(21):6165-71. PubMed ID: 12414643
[TBL] [Abstract][Full Text] [Related]
10. Targeted expression of herpes simplex virus thymidine kinase in adenovirus-infected cells reduces virus titers upon treatment with ganciclovir in vitro.
Ibrišimović M; Nagl U; Kneidinger D; Rauch M; Lion T; Klein R
J Gene Med; 2012 Jan; 14(1):3-19. PubMed ID: 22190534
[TBL] [Abstract][Full Text] [Related]
11. Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase.
Oh JY; Park MY; Kim DR; Lee JH; Shim SH; Chung JH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
Int J Mol Med; 2010 Mar; 25(3):369-76. PubMed ID: 20127041
[TBL] [Abstract][Full Text] [Related]
12. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
Palmer DH; Chen MJ; Searle PF; Kerr DJ; Young LS
Gene Ther; 2005 Aug; 12(15):1187-97. PubMed ID: 15800660
[TBL] [Abstract][Full Text] [Related]
14. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
[TBL] [Abstract][Full Text] [Related]
15. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy.
Lambright ES; Amin K; Wiewrodt R; Force SD; Lanuti M; Propert KJ; Litzky L; Kaiser LR; Albelda SM
Gene Ther; 2001 Jun; 8(12):946-53. PubMed ID: 11426335
[TBL] [Abstract][Full Text] [Related]
16. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
[TBL] [Abstract][Full Text] [Related]
17. Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy.
Oosterhoff D; van Beusechem VW
J Exp Ther Oncol; 2004 Apr; 4(1):37-57. PubMed ID: 15255291
[TBL] [Abstract][Full Text] [Related]
18. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors.
van Beusechem VW; Mastenbroek DC; van den Doel PB; Lamfers ML; Grill J; Würdinger T; Haisma HJ; Pinedo HM; Gerritsen WR
Gene Ther; 2003 Nov; 10(23):1982-91. PubMed ID: 14528322
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus.
Lee CT; Park KH; Yanagisawa K; Adachi Y; Ohm JE; Nadaf S; Dikov MM; Curiel DT; Carbone DP
Cancer Res; 2004 Sep; 64(18):6660-5. PubMed ID: 15374981
[TBL] [Abstract][Full Text] [Related]
20. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Wang HE; Yu HM; Liu RS; Lin M; Gelovani JG; Hwang JJ; Wei HJ; Deng WP
J Nucl Med; 2006 Jul; 47(7):1161-71. PubMed ID: 16818951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
